Sign in
Not yet taking people in United StatesPhase 4

Study of Remimazolam for Cataract Surgery

Key facts

Who runs it
Fred E, Shapiro
Where
Boston, United StatesSee the site
Trial code
Status
Not yet recruiting
Phase
Phase 4
People taking part
30 people, planned
Started
15 Sept 2026
Expected to end
1 Jun 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Arm 1 Cataract Surgery performed with remimazolam as sedative
  • Arm 2 Cataract Surgery performed with standard of care sedative
Record updated
15 July 2026

Who can take part

Age
55 years to 90 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Subject is planning to have cataract surgery in both eyes
  • The surgeon estimates that each cataract surgery are estimated to take less than 30 minutes
  • Subject is aged 55 to 90 years old
  • Surgeries will take place on the main campus of Mass Eye and Ear at 243 Charles St., Boston for at least the first year. In the future, surgeries may also occur at Mass Eye and Ear Longwood Surgical Ambulatory Care Center
  • Subject is able to understand the consent form and sign the consent
  • ASA 1-3 (possible breakdown numbers of 5, 10, 10, 5)

Who cannot take part

  • Subject uses concomitant home narcotic or anxiolytic
  • Subject has a history of difficulty with sedation during procedures
  • Subject has a history of cognitive decline
  • A history of severe hepatic impairment
  • The surgeon estimates that one of the planned cataract surgeries is estimated to take longer than 30 minutes
  • Subject uses O2

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 55 and 90 years old?

Where in United States

  • Massachusetts Eye and Ear InfirmaryBoston, United StatesContact: Vikranth R. Chinthareddy, BANot yet recruiting

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if the use of the sedative remimazolam improves the safety of patients having cataract surgery by decreasing the number of sedation-related complications during and after surgery, and shortening post-surgical cognitive recovery time.

The 2 groups in the trial

  • Arm 1 Cataract Surgery performed with remimazolam as sedativeTreatment being tested

    Subjects are serving as their own control. Subjects are scheduled for cataract surgery in both eyes. Sedation will be remimazolam in one eye and the standard of care in the other eye. The order of sedation will be randomly determined (50% of subjects will have remimazolam in the first eye surgery and 50% will have it in the second eye surgery.) Subjects will be blinded as to which sedation is provided at each surgery.

  • Arm 2 Cataract Surgery performed with a standard of care sedativePlacebo, for comparison

    Subjects are serving as their own control. Subjects are scheduled for cataract surgery in both eyes. Sedation in this arm will be the standard of care. The order of sedation will be randomly determined (50% of subjects will have remimazolam in the first eye surgery and 50% will have it in the second eye surgery.) Subjects will be blinded as to which sedation is provided at each surgery.

    Treatment: Arm 2 Cataract Surgery performed with standard of care sedative

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Remimazolam for Sedation in Cataract Surgery, A Phase IV, On-label, Blinded Study
Criteria questions
Built from NCT07325227, who can take part
Record updated
15 July 2026